Cirrus Therapeutics is an ocular immunology-focused company co-founded by Dr. Kai Chan, former Chief Scientific Officer of Ally Therapeutics and Blavatnik Fellow at Harvard Business School, and Dr. Andrew Dick, Professor and Head of the Academic Unit of Ophthalmology at the University of Bristol and Director of UCL Institute of Ophthalmology.
Cirrus, a spin-out from the University of Bristol, is developing treatments for long-term eye diseases that can cause blindness, focusing on conditions that affect the ocular immune system.
Cirrus’ lead program is a differentiated and first-in-class approach to treating dry age-related macular degeneration (AMD), the leading cause of vision loss among older adults.
Dr. Dick, Dr. Chan, and colleagues found that increasing the protein IRAK-M in retinal cells can significantly protect against retinal degeneration. This discovery will build and improve upon current treatments for AMD, which only have the capacity to address single pathophysiology pathways.
Cirrus’ novel approach not only addresses the multiple pathways involved in treating AMD but also offers the most compelling and evidence-based strategy available today.
MARKET POTENTIAL
The AMD market is rapidly growing—especially as global populations age—and is expected to reach $27.5 billion by 2031.
Company Details
- Employees
- 4
- Address
- Single Pathophysiology Pathways.
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
Cirrus Therapeutics Questions
Cirrus Therapeutics's LinkedIn profile is https://www.linkedin.com/company/cirrus-therapeutics
Cirrus Therapeutics has
4 employees.
View email and phone details for 4
employees at Cirrus Therapeutics.
Cirrus Therapeutics's industry is
Biotechnology Research
Cirrus Therapeutics's top competitors are
Lime Therapeutics,
Unravel Biosciences,
Ally Therapeutics, Inc.,
Larkspur Biosciences,
Cyclera Therapeutics,
Kiragen Bio,
Nandi Life Sciences Llc,
Droplet Biosciences, Inc,
Astrivax Therapeutics,
Kano Therapeutics.
Cirrus Therapeutics's categories are Biotechnology Research
